Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tirzepatide
Biotech
Lilly's next focus: Testing incretins in neuro, immunology fields
“We'll be prepared to move rapidly into phase 3 trials based on clinical data and where our conviction is high,” Lilly's CSO Daniel Skovronsky said.
Gabrielle Masson
Feb 6, 2025 2:35pm
Biolexis enters small molecule into oral GLP-1 horse race
Sep 13, 2024 12:24pm
Arrowhead dips toes into obesity pond with 2 preclinical assets
Aug 14, 2024 3:50pm
The most valuable R&D projects? You guessed it: obesity
Jul 11, 2024 5:00am
Viking's MASH drug scores where Madrigal's didn't
Jun 4, 2024 1:51pm
A look at the R&D landscape in obesity, led by GLP-1s
Mar 19, 2024 8:00am